Roche Withdraws Immunotherapy in U.S. for Bladder Cancer After Failed Study

Tecentriq failed to beat chemotherapy in improving overall survival, the main goal of its confirmatory Phase 3 test in bladder cancer. The drug had been granted accelerated approval based on results from a single-arm Phase 2 clinical trial.